<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="21%"></col>
<col width="79%"></col>
<tbody>
<tr>
<td colspan="2" stylecode="Rrule Botrule Lrule Toprule " valign="middle">
<list listtype="unordered">
<item>
<caption> </caption>
<content stylecode="bold">Gemfibrozil </content>
</item>
</list>
</td>
</tr>
<tr>
<td align="center" stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>Gemfibrozil significantly increased repaglinide exposures by 8.1 fold <content stylecode="italics">[see <linkhtml href="#ID_838f2389-ca01-4cbb-a214-e39ce59222c8">Clinical Pharmacology</linkhtml> (<linkhtml href="#ID_0a69ca30-fc6f-49e1-9c5d-df3c3b145ccd">12.3</linkhtml>)] </content>
</paragraph>
</td>
</tr>
<tr>
<td align="center" stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>Do not administer PRANDIN to patients receiving gemfibrozil <content stylecode="italics">[see <linkhtml href="#ID_ca722563-9705-46e6-a292-a71b18d14e53">Contraindications</linkhtml> (<linkhtml href="#ID_ca722563-9705-46e6-a292-a71b18d14e53">4</linkhtml>)]</content>.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption> </caption>
<content stylecode="bold">Clopidogrel</content>
</item>
</list>
</td>
</tr>
<tr>
<td align="center" stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>Clopidogrel increased repaglinide exposures by 3.9-5.1 fold <content stylecode="italics">[see <linkhtml href="#ID_838f2389-ca01-4cbb-a214-e39ce59222c8">Clinical Pharmacology</linkhtml> (<linkhtml href="#ID_0a69ca30-fc6f-49e1-9c5d-df3c3b145ccd">12.3</linkhtml>)]</content>
</paragraph>
</td>
</tr>
<tr>
<td align="center" stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>Avoid concomitant use of PRANDIN with clopidogrel.  If concomitant use can not be avoided, initiate PRANDIN at 0.5 mg before each meal and do not exceed a total daily dose of 4 mg  <content stylecode="italics">[see <linkhtml href="#ID_c1f2e4f9-e00c-48db-a1ef-05e2ee217105">DOSAGE AND ADMINISTRATION</linkhtml> (<linkhtml href="#ID_74bbf313-f24b-40d3-b1a8-e0ca2fa73f47">2.3</linkhtml>)]</content>. Increased frequency of glucose monitoring may be required during concomitant use.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption> </caption>
<content stylecode="bold">Cyclosporine</content>
</item>
</list>
</td>
</tr>
<tr>
<td align="center" stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>Cyclosporine increased low dose repaglinide exposures by 2.5 fold <content stylecode="italics">[see <linkhtml href="#ID_838f2389-ca01-4cbb-a214-e39ce59222c8">Clinical Pharmacology</linkhtml> (<linkhtml href="#ID_0a69ca30-fc6f-49e1-9c5d-df3c3b145ccd">12.3</linkhtml>)]</content>
</paragraph>
</td>
</tr>
<tr>
<td align="center" stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>Daily maximum PRANDIN dose should be limited to 6 mg, and increased frequency of glucose monitoring may be required when PRANDIN is co-administered with cyclosporine.  </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption> </caption>
<content stylecode="bold">CYP2C8 and CYP3A4 Inhibitors</content>
</item>
</list>
</td>
</tr>
<tr>
<td align="center" stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>PRANDIN dose reductions and increased frequency of glucose monitoring may be required when co-administered.</paragraph>
</td>
</tr>
<tr>
<td align="center" stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>Drugs that are known to inhibit CYP3A4 include antifungal agents (ketoconazole, itraconazole) and antibacterial agents (clarithromycin, erythromycin). Drugs that are known to inhibit CYP2C8 include  trimethoprim, gemfibrozil, montelukast, deferasirox, and clopidiogrel.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption> </caption>
<content stylecode="bold">CYP2C8 and CYP3A4 Inducers</content>
</item>
</list>
</td>
</tr>
<tr>
<td align="center" stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>PRANDIN dose increases and increased frequency of glucose monitoring may be required when co-administered.</paragraph>
</td>
</tr>
<tr>
<td align="center" stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>Drugs that induce the CYP3A4 and/or 2C8 enzyme systems include rifampin, barbiturates, and carbamezapine</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption> </caption>
<content stylecode="bold">Drugs That May Increase the Risk of Hypoglycemia</content>
</item>
</list>
</td>
</tr>
<tr>
<td align="center" stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>PRANDIN dose reductions and increased frequency of glucose monitoring may be required when co-administered.</paragraph>
</td>
</tr>
<tr>
<td align="center" stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption> </caption>
<content stylecode="bold">Drugs That May Decrease the Blood Glucose Lowering Effect of PRANDIN</content>
</item>
</list>
</td>
</tr>
<tr>
<td align="center" stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>PRANDIN dose increases and increased frequency of glucose monitoring may be required when co-administered.</paragraph>
</td>
</tr>
<tr>
<td align="center" stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption> </caption>
<content stylecode="bold">Drugs That May Blunt Signs and Symptoms of Hypoglycemia</content>
</item>
</list>
</td>
</tr>
<tr>
<td align="center" stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>Increased frequency of glucose monitoring may be required when PRANDIN is co-administered with these drugs.</paragraph>
</td>
</tr>
<tr>
<td align="center" stylecode="Rrule Botrule Lrule " valign="middle">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Botrule Lrule " valign="middle">
<paragraph>beta-blockers, clonidine, guanethidine, and reserpine</paragraph>
</td>
</tr>
</tbody>
</table>